— Know what they know.
Not Investment Advice

MRNS NASDAQ

Marinus Pharmaceuticals, Inc.
1W: +0.6% 1M: +2.4% 3M: +53.2% 1Y: -78.0% 3Y: -78.8% 5Y: -74.3%
$0.55
Last traded 2025-02-11 — delisted
NASDAQ · Healthcare · Biotechnology · $30.4M mcap · 37M float · 4.84% daily turnover

Cash Flow Trends

Operating Cash Flow
-$118M -4.5% ▼
Capital Expenditures
$119K +93.3% ▲
5Y CAGR: +7.5%
Free Cash Flow
-$118M -3.0% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$120M -202.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
— Operating Activities —
Net Income-$54M-$67M-$99M-$20M-$141M
Depreciation & Amort.$278K$334K$355K$418K$551K
Stock-Based Comp.$6M$8M$14M$15M$16M
Change in Working Capital-$590K-$2M$29M-$6M$2M
Other Non-Cash Items$94K$626K$1M-$102M$5M
Operating Cash Flow-$49M-$61M-$55M-$113M-$118M
— Investing Activities —
Capital Expenditures-$388K$0-$3M-$2M-$119K
Acquisitions (Net)-$4M$0$0$171K$0
Investment Purchases-$3M-$9M$0-$171K-$52M
Investment Sales$7M$8M$1M$107M$24M
Other Investing$4M-$738K$1M$171K$9K
Investing Cash Flow$4M-$738K-$1M$106M-$29M
— Financing Activities —
Net Debt Issuance$0$0$40M$59M$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$97K$1M$1M$2M$804K
Financing Cash Flow$68M$109M$41M$125M$27M
Net Change in Cash$23M$48M-$16M$118M-$120M
Cash End of Period$91M$139M$123M$241M$121M
Free Cash Flow-$49M-$61M-$58M-$115M-$118M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms